| Primary |
| Non-hodgkin's Lymphoma |
20.3% |
| Product Used For Unknown Indication |
10.6% |
| Burkitt's Lymphoma |
8.1% |
| Ewing's Sarcoma |
7.2% |
| Cervix Carcinoma Stage Iv |
6.8% |
| Drug Use For Unknown Indication |
6.4% |
| Premedication |
6.4% |
| Drug Exposure During Pregnancy |
5.9% |
| Lymphoma |
5.9% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Prophylaxis Of Nausea And Vomiting |
3.0% |
| Sarcoma Metastatic |
2.5% |
| Bone Sarcoma |
2.1% |
| Primitive Neuroectodermal Tumour |
2.1% |
| Rhabdomyosarcoma |
2.1% |
| Cystitis Haemorrhagic |
1.7% |
| Diffuse Large B-cell Lymphoma |
1.7% |
| Maternal Exposure During Pregnancy |
1.7% |
| Bone Marrow Conditioning Regimen |
1.3% |
| Metastasis |
1.3% |
|
| Febrile Neutropenia |
18.6% |
| Convulsion |
14.0% |
| Anaemia |
9.3% |
| Encephalopathy |
9.3% |
| Dystonia |
4.7% |
| Pancytopenia |
4.7% |
| Pneumonia |
4.7% |
| Pyrexia |
4.7% |
| Vomiting |
4.7% |
| Adverse Event |
2.3% |
| Anaphylactic Reaction |
2.3% |
| Ascites |
2.3% |
| Caesarean Section |
2.3% |
| Drug Eruption |
2.3% |
| Extravasation |
2.3% |
| Face Oedema |
2.3% |
| Haematuria |
2.3% |
| Hepatitis B |
2.3% |
| Leukopenia |
2.3% |
| Mucosal Inflammation |
2.3% |
|
| Secondary |
| Sarcoma |
13.5% |
| Lymphoma |
10.4% |
| Burkitt's Lymphoma |
8.8% |
| Hodgkin's Disease |
8.2% |
| Acute Lymphocytic Leukaemia |
7.5% |
| Sarcoma Metastatic |
6.7% |
| Product Used For Unknown Indication |
6.3% |
| Rhabdomyosarcoma |
5.9% |
| Drug Use For Unknown Indication |
4.9% |
| Non-hodgkin's Lymphoma |
4.3% |
| Prophylaxis |
3.5% |
| Mantle Cell Lymphoma |
3.2% |
| Synovial Sarcoma |
2.9% |
| B-cell Lymphoma |
2.4% |
| Medulloblastoma |
2.4% |
| Diffuse Large B-cell Lymphoma |
2.3% |
| Metastases To Lung |
1.8% |
| Germ Cell Cancer |
1.7% |
| Ewing's Sarcoma |
1.6% |
| T-cell Lymphoma |
1.5% |
|
| Febrile Neutropenia |
12.7% |
| Off Label Use |
12.7% |
| Vomiting |
7.7% |
| Encephalopathy |
5.9% |
| Thrombocytopenia |
5.7% |
| Death |
5.0% |
| Sepsis |
5.0% |
| Mucosal Inflammation |
4.8% |
| Fatigue |
4.5% |
| Hepatotoxicity |
4.5% |
| Pyrexia |
3.9% |
| White Blood Cell Count Decreased |
3.9% |
| Toxicity To Various Agents |
3.6% |
| Renal Failure Acute |
3.4% |
| Infection |
3.2% |
| Urinary Tract Infection |
3.2% |
| Back Pain |
2.9% |
| Epistaxis |
2.7% |
| Nephropathy Toxic |
2.5% |
| Bone Pain |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.1% |
| Prophylaxis |
13.5% |
| Drug Use For Unknown Indication |
9.6% |
| Prophylaxis Of Nausea And Vomiting |
7.8% |
| Neuroblastoma |
5.1% |
| Bone Marrow Conditioning Regimen |
4.9% |
| Acute Lymphocytic Leukaemia |
4.7% |
| Prophylaxis Against Graft Versus Host Disease |
4.4% |
| B-cell Lymphoma |
3.9% |
| Premedication |
3.7% |
| Infection Prophylaxis |
3.2% |
| Chemotherapy |
3.2% |
| Antifungal Prophylaxis |
2.4% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
2.4% |
| Non-hodgkin's Lymphoma |
2.0% |
| Mantle Cell Lymphoma |
1.9% |
| Pain |
1.7% |
| Aplastic Anaemia |
1.6% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Antiviral Prophylaxis |
1.4% |
|
| Neutropenia |
9.4% |
| Febrile Neutropenia |
8.3% |
| Thrombocytopenia |
7.6% |
| Vomiting |
7.6% |
| Wrong Technique In Drug Usage Process |
5.8% |
| Pyrexia |
5.5% |
| Sepsis |
5.5% |
| White Blood Cell Count Decreased |
5.1% |
| Vena Cava Thrombosis |
4.8% |
| Pulmonary Embolism |
4.6% |
| Septic Shock |
4.6% |
| Encephalopathy |
4.1% |
| Mucosal Inflammation |
3.9% |
| Pneumonia |
3.9% |
| Cystitis Haemorrhagic |
3.5% |
| White Blood Cell Count Increased |
3.5% |
| Bacteraemia |
3.2% |
| Respiratory Failure |
3.2% |
| Staphylococcal Sepsis |
3.0% |
| Venoocclusive Liver Disease |
2.8% |
|
